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Over the past 2 decades, the treatment of type 2 diabetes mellitus (T2DM) has been an evolving science. With therapeutic advances, the preva-
lence of catastrophic complications such as amputations, 
renal failure requiring dialysis, and blindness due to ret-
inopathy have significantly declined. Developed drugs 
have successfully met treatment goals; however, they are 
often associated with a higher risk of hypoglycemia and 
weight gain. Now that better glucose control is possible, 
the science of diabetes care continues to evolve. Newly 
developed drugs should control glucose without signif-
icant hypoglycemia and also promote weight reduction. 
The sodium-glucose transport protein 2 (SGLT2) inhib-
itor drug class has these characteristics, and the novel 
mechanism of action complements older medications 
used to treat T2DM.
Phlorizin is a plant-based compound originally discov-
ered in 1935 when it was derived from the bark of apple 
trees.1 It is a naturally occurring botanical glucoside and is 
fairly nonselective between SGLT1 and SGLT2. Due to its 
poor bioavailability and its degradation in the gastrointes-
tinal tract, it was not an ideal drug candidate in humans. 
However, it stood as a starting point for the development 
of the current gliflozin class of SGLT2 inhibitors cana-
gliflozin, dapagliflozin, and empagliflozin, which are re-
viewed in this article. The Table outlines the differences 
between the drugs. The eTable (available at www.fedprac 
.com) highlights clinical trial data for each drug.
CANAGLIFLOZIN
Canagliflozin is a SGLT2 inhibitor and a low-potency 
SGLT1 inhibitor. It was the first SGLT2 inhibitor ap-
proved by the FDA (March 2013) to be used with diet 
and exercise to improve glycemic control in adults with 
T2DM. The recommended starting dose is 100 mg once 
daily for patients who have an estimated glomerular fil-
tration rate (eGFR) > 60 mL/min/1.73m2 and can be 
increased to 300 mg once daily. It is also available in a 
fixed-dose combination with metformin. Canagliflozin 
SGLT-2 inhibition leads to increased glycosuria and os-
motic diuresis that lowers plasma glucose concentra-
tions. Lower blood pressure (BP) is likely an effect of 
the osmotic diuresis. Increased urinary excretion of glu-
cose also leads to a loss of calories and weight loss. It was 
studied alone and in combination with metformin, sulfo-
nylurea, pioglitazone, and insulin therapy. 
The pharmacokinetics of canagliflozin is similar in 
healthy subjects and patients with T2DM. Peak plasma 
concentrations (Cmax) and area under the cover (AUC) 
of canagliflozin increased in a dose-proportional manner 
from 50 mg to 300 mg. Following single-dose oral ad-
ministration of 100 mg and 300 mg of canagliflozin, time 
to Cmax (Tmax) of canagliflozin occurs within 1 to 2 hours 
postdose. The apparent terminal half-life (t1/2) was 
10.6 hours and 13.1 hours for the 100 mg and 300 mg 
doses, respectively. Steady state was reached after 4 to 
5 days of once-daily dosing with canagliflozin 100 mg to 
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300 mg. Glucuronidation is the major metabolic pathway. 
There is balanced renal and biliary excretion of metabo-
lites, and there are no active metabolites. 
Following oral doses of canagliflozin in patients with 
T2DM, dose-dependent decreases were seen in the renal 
threshold for glucose (RTG). From a starting value of 
about 240 mg/dL, the 300-mg dose suppressed the mean 
(RTG) to about 70 to 90 mg/dL in T2DM in phase 1 
studies. The reduction in RTG led to increase in urinary 
excretion of glucose of about 100 g/d. 
In addition to renal SGLT2 inhibition leading to in-
creased urinary glucose excretion (UGE), canagliflozin 
has been shown to lower postprandial glucose excur-
sion (PPGE) and insulin concentrations by delaying 
intestinal glucose absorption.2 A study was done in 
20 healthy subjects who received either placebo or 
canagliflozin 300 mg 20 minutes before a 600 kcal 
mixed-meal tolerance test. Compared with placebo, 
canagliflozin reduced PPGE and insulin excursions 
(0-2 h) AUC by 35% and 43%, respectively (P < .001 
for both). This may present a difference between cana-
gliflozin and the other SGLT2 inhibitors.
Because of the potential differences due to cana-
gliflozin’s inhibition of intestinal SGLT1, the pharmacody-
namic differences between canagliflozin and dapagliflozin 
were studied.3 The randomized, double-blind, crossover 
study consisted of 54 subjects. The subjects received the 
maximum approved doses of canagliflozin 300 mg or 
dapagliflozin 10 mg a day. Each group was treated with the 
study drug for 2 days, and then a 600 kcal mixed-meal tol-
erance test was performed. The results of the PPGE 0- to 
2-hour AUC analysis showed 3.66 mmol*h/L with cana-
gliflozin 300 mg and 4.08 mmol*h/L with dapagliflozin 
10 mg. There was a difference 
of 0.42 (P = .0122), which was a 
10.3% reduction in AUC PPGE 
by canagliflozin compared with 
dapagliflozin. 
Canagliflozin has been studied in 
patients with T2DM and stage 3 ne-
phropathy. Data were pooled from 4 ran-
domized, placebo-controlled, phase 3 
studies in which subjects had baseline 
eGFR > 30 to < 60 mL/min/1.73 m2.4 
In the setting of decreased eGFR associ-
ated with stage 3 chronic kidney disease, 
subjects treated with canagliflozin 100 mg and canagliflozin 
300 mg had placebo-subtracted reductions in hemoglobin 
A1c (A1c) of -0.38% and -0.47%, respectively, and placebo-
subtracted reduction in weight of -1.6% and -1.9%, respec-
tively. Decreases in eGFR were seen at week 6 but trended 
toward baseline over time with a mean change in eGFR of 
0.7, -1.7, -2.2 mL/min/1.73 m2 for placebo, canagliflozin 
100 mg, and canagliflozin 300 mg, respectively. 
Clinical Efficacy Trials
Canagliflozin was studied as add-on therapy to met-
formin and compared with glimepiride (a sulfonyl-
urea).5 The randomized, double-blind study included 
1,450 subjects for a core study period of 52 weeks fol-
lowed by a 52-week extension. Eligible subjects were 
aged > 18 and < 80 years, A1c > 7% and < 9.5%, and 
were receiving metformin > 2,000 mg/d or > 1,500 mg/d 
if unable to tolerate a higher dose. The study groups 
were canagliflozin 100 mg, canagliflozin 300 mg, and 
glimepiride, and baseline A1c measurements were 7.78%, 
7.79%, and 7.83%, respectively. The glimepiride was ti-
trated up if > 50% of fasting blood glucose measure-
ments were > 108 mg/dL with no hypoglycemic events 
in the previous 2 weeks. 
Over 104 weeks, canagliflozin 100 mg and 300 mg 
and glimepiride reduced A1c from mean baseline val-
ues by -0.65%, -0.74%, and -0.55%, respectively, and 
the proportions of patients achieving A1c < 7% at week 
104 was 42.5%, 50.2%, and 43.9%, respectively. Weight 
fell over 104 weeks with canagliflozin 100 mg (-4.1%, 
-3.6 kg) and canagliflozin 300 mg (-4.2%, -3.6 kg). In 
contrast, glimepiride showed weight increase (0.9%, 
0.8 kg). Documented hypoglycemia episodes were 
Table. SGLT2 Inhibitor Drugs
Canagliflozin Dapagliflozin Empagliflozin
Starting dose 100 mg qd 5 mg qd 10 mg qd
Maintenance dose 300 mg qd 10 mg qd 25 mg qd
< eGFR (mL/min/1.73 m2) 
not recommended
< 45 < 60 < 45
SGLT1 effects Yes No No
Abbreviations: eGFR, estimated glomerular filtration rate; qd, once daily; SGLT, sodium-glucose 
transport protein.
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lower in canagliflozin 100 mg and 300 mg than with 
glimepiride (6.8%, 8.2%, and 40.9%, respectively). 
 A study was undertaken to compare canagliflozin 
with the dipeptidyl peptidase-4 (DPP-4) inhibitor si-
tagliptin in patients with T2DM on background ther-
apy of metformin.6 This randomized, double-blind trial 
studied subjects aged > 18 and < 80 years with inade-
quate glucose control A
1c 
> 7% and < 10.5%. Subjects 
received metformin > 2,000 mg/d or > 1,500 mg/d if 
unable to tolerate a higher dose. At week 52, cana-
gliflozin showed noninferiority to sitagliptin, with both 
drugs lowering A
1c
 by 0.73%. Canagliflozin 300 mg 
showed superiority to sitagliptin with -0.88% change 
in A
1c
. Both canagliflozin 100 mg and 300 mg were su-
perior to sitagliptin 100 mg in weight reduction: -3.8%, 
-4.2%, and -1.3%, respectively. Genital mycotic infec-
tions were higher in the canagliflozin groups. Rates for 
mycotic infections for sitagliptin 100 mg, canagliflozin 
100 mg, and canagliflozin 300 mg were 1.2%, 5.2%, 
and 2.4% in men, respectively, and 2.6%, 11.3%, and 
9.9% in women, respectively. 
Canagliflozin was also studied in combination with 
insulin to determine efficacy and safety in this setting.7 
Subjects were randomized to receive placebo, cana-
gliflozin 100 mg, or canagliflozin 300 mg. Subjects had 
a mean baseline A1c of 8.3%. The median daily insulin 
dose was 60 IU, and most individuals were using basal/
bolus regimens. The primary endpoint was 18 weeks 
of therapy, and A1c was lowered 0.62% (P < .001) with 
canagliflozin 100 mg and 0.73% with canagliflozin 
300 mg compared with placebo. Weight decreased 1.9% 
(P < .001) with canagliflozin 100 mg and 2.4% (P < .001) 
with canagliflozin 300 mg compared with placebo. 
Adverse Effects and Precautions
Canagliflozin adverse effects (AEs) were generally low. 
In the aforementioned 104-week study comparing cana-
gliflozin 100 mg, canagliflozin 300 mg, and glimepiride, 
AEs leading to discontinuation were low at 6.2%, 9.5%, 
and 7.3%, respectively. Serious AEs were lower in the 
canagliflozin 100 mg and 300 mg groups compared with 
glimepiride at 9.7%, 9.7%, 14.3%, respectively.5
Limitations for use of canagliflozin are T1DM and di-
abetic ketoacidosis (DKA). In mild renal impairment, 
there is no dose adjustment in patients with eGFR 
> 60 mL/min/1.73 m2. In moderate renal impairment 
(eGFR 45-60 mL/min/1.73 m2), dose is limited to 100 mg 
once daily. It is recommended not to initiate canagliflozin 
if eGFR is < 45 mL/min/1.73 m2. Canagliflozin is contra-
indicated if eGFR is < 30 mL/min/1.73 m2.8
DAPAGLIFLOZIN
Dapagliflozin is a highly selective SGLT2 inhibitor. It is 
a 1,400-fold greater inhibitor of SGLT2 vs SGLT1 and 
was approved in January 2014. It is indicated as an ad-
junct to diet and exercise to improve glycemic control 
in adults with T2DM. The recommended starting dose 
is 5 mg once daily, taken in the morning, with or with-
out food, and the dosage can be increased to 10 mg once 
daily in patients who require additional glycemic con-
trol. Dapagliflozin should not be initiated if eGFR is 
< 60 mL/min/1.73 m2, and it should be discontinued if 
eGFR is persistently < 60 mL/min/1.73 m2. 
By inhibiting SGLT2, dapagliflozin reduces reabsorp-
tion of filtered glucose and lowers the renal threshold for 
glucose, thereby increasing UGE. Increased glucose se-
cretion also leads to weight reduction. Dapagliflozin has 
been studied alone and in combination with glipizide, 
glimepiride, pioglitazone, and a DDP-4 inhibitor and as 
an add-on to insulin with and without other oral antidi-
abetic drugs. It is also available in a fixed-dose combina-
tion with metformin. 
Following oral administration of dapagliflozin, the 
Tmax is usually attained within 2 hours under a fasting 
state. The Cmax and AUC values increase the dose pro-
portionally with increase in dapagliflozin dose in the 
therapeutic dose range. The absolute oral bioavailabil-
ity of dapagliflozin following the administration of a 
10-mg dose is 78%. The mean plasma t1⁄2 for dapa-
gliflozin is about 12.9 hours following a single oral 
dose of 10 mg. In patients with normal renal func-
tion, the renal glucose excretion was 85 g per day at 
maximal dose. In humans, 75% of the dose of dapa-
gliflozin is primarily metabolized through the uridine 
diphosphate glucuronosyltransferase 1A9 pathway. 
Dapagliflozin and related metabolites are primarily 
eliminated via the renal pathway.9
Clinical Efficacy Trials
Dapagliflozin was studied as add-on therapy to metfor-
min with glipizide (a sulfonylurea) as the comparator.10 
This 52-week double-blind, multicenter, active-controlled, 
noninferiority trial randomized 801 patients. Eligible sub-
jects were aged > 18 years with A1c > 6.5% and < 10% 
and were receiving metformin or metformin and 1 other 
oral antidiabetic drug up to half-maximal dose for at least 
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8 weeks. During an 18-week titration period, all patients 
started dapagliflozin 2.5 mg/d and glipizide 5 mg/d. At 
21-day intervals, patients were titrated up to the next dos-
age level if fasting plasma glucose was > 110 mg/dL. Dapa-
gliflozin could be titrated to 5 mg and then 10 mg per 




 change with dapagliflozin was noninferior 
to glipizide at week 52. The A
1c
 adjusted mean change 
from baseline was -0.52 for both dapagliflozin and glip-
izide. The secondary endpoint was weight change. The 
glipizide group had a +1.44 kg weight gain, whereas the 
dapagliflozin group had a -3.22 kg weight loss. The num-
ber of patients with ≥ 1 episode of hypoglycemia, either 
symptomatic or with no symptoms, with blood glucose 
≤ 63 mg/dL was assessed. The dapagliflozin group had a 
3.5% rate compared with the glipizide group, which had 
a 40.8% rate of patients with > 1 hypoglycemic episode. 
A study examined the efficacy and safety of dapa-
gliflozin in combination with and also vs a DPP-4 in-
hibitor with metformin background therapy. The study 
looked at add-ons of saxagliptin plus dapagliflozin vs sax-
agliptin or dapagliflozin added alone.11 This was a ran-
domized, double-blind, 24-week study with patients aged 
> 18 years with inadequate glucose control A1c > 8.0% 
and < 12.0%. Patients had to be on a stable dose of met-
formin > 1,500 mg/d for at least 8 weeks. Patients were 
randomized 1:1:1 to receive either saxagliptin 5 mg/d and 
dapagliflozin 10 mg/d plus metformin, saxagliptin 5 mg/d 
and placebo plus metformin, or dapagliflozin 10 mg/d 
and placebo plus metformin. 
The patients had a mean age of 54 years and a mean 
duration of T2DM of 7.6 years. The mean baseline A1c 
was 8.94%. The addition of saxagliptin plus dapagliflozin 
to metformin resulted in significantly greater A1c reduc-
tion compared with saxagliptin plus metformin or dapa-
gliflozin plus metformin from baseline A1c levels: -1.47%, 
-0.88%, -1.2%, respectively.11 
Dapagliflozin was also studied in combination with 
insulin to determine the safety and efficacy in this set-
ting.12 This double-blind, placebo-controlled, paral-
lel-group trial had an initial study period of 24 weeks 
followed by an extension period totaling 104 weeks. At 
48 weeks, patients on dapagliflozin 5 mg were switched 
to 10 mg. Outcomes over 104 weeks were changed from 
baseline A1c, insulin dose, and body weight. Up-titra-
tion of insulin was permitted if at least 3 self-monitored 
blood glucose readings from the 7 days prior to the study 
visit were > 240 mg/dL up to week 12; > 220 mg/dL be-
tween weeks 12 and 24; > 178 mg/dL or if A
1c
 was > 8% 
between weeks 24 and 48. Between weeks 52 and 65, 
insulin titrated up was allowed if A
1c
 was > 7.5% and 
 between weeks 78 and 104 if A
1c
 was > 7%. Insulin could 
be titrated down if ≥ 2 self-monitored blood glucose read-
ings were < 68 mg/dL. 
The study group had a T2DM diagnosis for 13.6 years 
and a mean duration of insulin therapy for about 6 years. 
The mean daily insulin dose was 77.1 IU. The mean base-
line A
1c
 was 8.5%. At 104 weeks, the differences from pla-
cebo in A
1c
 adjusted mean change from baseline were 
-4.0% (P = .0002) and -0.4% (P = .0007) in the dapa-
gliflozin 5 mg (switched to 10 mg at week 48) and 10 mg 
groups, respectively. Insulin requirements increased pro-
gressively in the placebo group +18.3 IU/d at 104 weeks. 
Insulin requirements stayed stable over 104 weeks in the 
dapagliflozin groups. Body weight increased in the pla-
cebo group, whereas it decreased in the dapagliflozin 
groups. At 104 weeks, the weight changes from baseline 
in placebo, dapagliflozin 5 mg/10 mg, and dapagliflozin 
10 mg were -0.99 kg, -1.03 kg (P < .001), and -1.5 kg 
(P < .0001), respectively. The frequency of ≥ 1 minor 
or major episodes of hypoglycemia was fairly balanced 
across placebo, dapagliflozin 5 mg/10 mg, and dapa-
gliflozin 10 mg at 61.9%, 61.3%, and 60.7%, respectively. 
Adverse Effects and Precautions
Dapagliflozin was generally well tolerated. In the trial of 
dapagliflozin compared with glipizide in the setting of 
metformin background therapy, AEs led to discontinua-
tion rates of 9.1% vs 5.9%, respectively. Serious AEs were 
lower in the dapagliflozin group compared with glipizide 
at 8.6% vs 11.3%, respectively.10
Limitations for use of dapagliflozin are the treat-
ment of T1DM or the treatment of DKA. Dapagliflozin 
should not be initiated in patients with an eGFR 
< 60 mL/min/1.73 m2. No dose adjustment is needed in 
patients with mild renal impairment (eGFR of ≥ 60 mL/
min/1.73 m2), and dapagliflozin should be discontin-
ued when eGFR is persistently < 60 mL/min/1.73 m2. In 
the clinical trials, there was an imbalance in the num-
ber of bladder cancer reported with dapagliflozin com-
pared with placebo. Across 22 clinical studies, newly 
diagnosed cases of bladder cancer were reported in 
10 of 6,045 patients (0.17%) treated with dapagliflozin 
and 1 of 3,512 patients (0.03%) treated with placebo or 
a comparator.9 There were too few cases to determine 
008_FP1015_DIabetes_Nyugen.FINAL.indd   13 11/12/15   9:58 AM
14S • FEDERAL PRACTITIONER • OCTOBER 2015
SGLT2 INHIBITORS 
www.fedprac.com
whether the emergence of these events is related to dapa-
gliflozin. Product labeling states dapagliflozin should 
not be used in patients with active bladder cancer and 
should be used with caution in those with a prior history 
of bladder cancer. 
EMPAGLIFLOZIN
Empagliflozin is the most recently FDA-approved SGLT2 
inhibitor (August 2014) for improved glycemic control in 
T2DM. It has the highest SGLT2 selectivity: > 2,500-fold 
selectivity for SGLT2 over SGLT1.13 Empagliflozin reg-
ulates blood glucose levels by increased UGE, indepen-
dent of endogenous insulin secretion. It is associated with 
modest reductions in body weight, visceral adiposity, and 
systolic BP.
Empagliflozin is available in 10-mg and 25-mg tablets, 
with a recommended initial dose of 10 mg daily.13 Dos-
ing adjustments are not required for geriatric patients or 
for those patients with hepatic impairment.14 The use of 
empagliflozin is contraindicated in patients with eGFR 
< 45 mL/min/1.73 m2 or for those whose eGFR declines 
to < 45 mL/min/1.73 m2 during therapy.15,16 Empagliflozin 
has a pregnancy risk category C. Drug transference dur-
ing lactation is unknown; therefore, empagliflozin during 
breast-feeding is not recommended. It is also available in a 
fixed-dose combination with metformin.
Empagliflozin has been studied alone and in com-
bination therapy with other oral antidiabetic drugs as 
well as insulin therapy. Metformin, pioglitazone, si-
tagliptin, and linagliptin have been studied in com-
bination with empagliflozin with sustained glycemic 
improvement without significantly increased risk of 
hypoglycemia.17-21 Empagliflozin/linagliptin combina-
tion was recently approved after phase 3 trials dem-
onstrated 62% of patients achieved an A1c value < 7% 
on the 25/5-mg dose at 24 weeks.21 Empagliflozin, co-
administered with multiple daily injections of insu-
lin (MDI), has been shown to safely improve glycemic 
control and reduce total daily insulin requirements 
without an increased risk of hypoglycemia.22 Currently, 
it is not approved for use in patients with T1DM, but 
phase 3 trials are ongoing.
Pharmacokinetics of empagliflozin among healthy 
volunteers paralleled those of people with T2DM with 
rapid absorption. The plasma glucose lowering effect 
of empagliflozin was evident after the first dose and be-
came more pronounced with treatment duration. The 
AUC and Cmax were dose-proportional over a range of 
empagliflozin doses in a single rising dose study, with 
maximum UGE of 90.8 g in healthy volunteers reached 
at the 400-mg dose.23 The T
max
 was 1.5 to 2.1 hours after 
dosing, comparable to dapagliflozin.24 Steady state with 
once-daily dosing is reached by day 5 with t1/2 range 
of 10 to 19 hours.24-27 Plasma levels of empagliflozin 
declined in a biphasic pattern, with a rapid distribu-
tion phase and a slower elimination phase. Total urine 
volume did not differ significantly in the empagliflozin 
group compared with placebo.
Healthy subjects treated with placebo or empagliflozin 
had comparable plasma glucose concentrations. Patients 
with T2DM demonstrated a decrease in mean daily glu-
cose of -37.0 mg/dL for the 10-mg dose compared with 
-13.5 mg/dL for placebo. Doses up to 10 mg were found 
to inhibit renal tubular reabsorption up to 40%, and 
higher doses inhibit up to 60% of filtered glucose.22-26 
Empagliflozin has been shown to have similar efficacy 
independent of food.27 The pharmacodynamic response 
declines with increasing renal impairment in SGLT2 in-
hibitors. Empagliflozin has been associated with a decline 
from UGE of 97.6 g in normal renal function to 18.2 g in 
severe renal impairment.
Phase 1 studies of healthy male volunteers initially 
elucidated empagliflozin’s therapeutic potential of dose-
dependent increases in UGE and associated reduction in 
A1c with daily administration, respectively.
24,28 Single ris-
ing dose studies further defined the linear pharmacoki-
netics and excellent tolerability of empagliflozin.23 Heise 
and colleagues demonstrated in 2 separate studies with 
multiple oral doses (2.5 mg, 10 mg, 25 mg, and 100 mg) 
of empagliflozin in people with T2DM similar pharmaco-
kinetics and efficacy in UGE, tolerability, and reduction 
in plasma glucose.24
Ferrannini and colleagues, in a 12-week phase 2 study, 
demonstrated a statistically significant reduction in A1c of 
0.5% and 0.6% with 10-mg and 25-mg doses, respectively, 
as well as a universal body weight decline by 2 kg.29
Clinical Efficacy Trials
A phase 3 trial of 1,549 randomized people with T2DM 
(aged > 18 years with baseline A1c of 7%-10%), comparing 
empagliflozin and glimepiride as an add-on to metformin, 
demonstrated noninferiority at 52 weeks and statisti-
cally significant superiority for the empagliflozin group 
at 104 weeks.30 The adjusted mean difference in change 
from baseline in A1c with empagliflozin vs glimepiride 
at week 104 was -0.11% (95% confidence interval, 
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-0.19 to -0.02; P = .0153 for superiority). Despite 39% 
of both groups achieving a A
1c
 < 7% at week 52, the 
empagliflozin group had significantly less hypoglyce-
mia (2% vs 24%). In the body composition substudy, 
empagliflozin demonstrated a significant reduction of 
3 kg compared with an increase of slightly over 1 kg in 
the glimepiride group at week 104. The majority of the 
empagliflozin-associated weight loss was found to be a 
reduction in fat mass. 
An international phase 2B randomized, controlled, 
open-label extension study of 659 people with T2DM 
(aged > 18 and < 79 years with a body mass index (BMI) 
< 40 kg/m2 and baseline A
1c
 of 7%-10%) described the 
long-term safety and efficacy of empagliflozin monother-
apy in combination with metformin as compared with si-
tagliptin monotherapy in combination with metformin. 
At week 90, the changes from baseline A1c were -0.34%/ 
-0.47% in the empagliflozin 10 mg/25 mg monotherapy 
group, -0.34%/0.63% in the empagliflozin 10 mg/25 mg/
metformin combination, -0.56% with metformin mono-
therapy, and -0.40% with sitagliptin/metformin combina-
tion.31 These data provided evidence that empagliflozin 
had sustained weight loss effects (-2.2 kg to -4.0 kg).
Empagliflozin monotherapy was studied with si-
tagliptin as an active comparator in a phase 3 trial of 
899 people with T2DM (aged > 18 years with baseline 
A1c of 7%-10%), with the primary endpoint of change in 
baseline in A1c at week 24. Both the 10-mg and 25-mg 
dose sof empagliflozin were associated with greater re-
ductions in A1c from baseline (-0.66%, -0.77%) at week 
24 than that of sitagliptin (-1.04%). Additionally, both 
doses of empagliflozin were associated with greater re-
ductions in bodyweight (-2.26 kg and -2.48 kg) as com-
pared with sitagliptin 100 mg (+0.18 kg).20
Empagliflozin’s efficacy and safety in combination 
with MDI insulin as well as add-on to basal insulin was 
tested in 2 separate studies.23,32 People with T2DM (mean 
age 58.8 years, A1c 8.2%) on basal insulin were random-
ized to empagliflozin (10 mg or 25 mg) or placebo for 
78 weeks with a constant basal insulin dose for the first 
18 weeks and titration allowed thereafter. Empagliflozin 
was found to significantly reduce A1c at both 18 and 
78 weeks (-0.48% and -0.64% for 10-mg/25-mg doses, 
respectively, vs -0.02% for placebo) and insulin dose at 
week 78 vs placebo (-8.8 IU on empagliflozin 10 mg 
and -11.2 IU on empagliflozin 25 mg).32 Similar rates of 
hypoglycemia were reported (36.1% of patients on 
empagliflozin and 35.3% on placebo). 
Furthermore, empagliflozin was studied in obese 
people with uncontrolled, insulin-dependent T2DM 
(A
1c 
8.3%, BMI 34.8 kg/m2) on MDI insulin (average 
92 IU/d) over a 52-week study.22 Patients were random-
ized to once-daily empagliflozin 10 mg, empagliflozin 
25 mg, or placebo. The study demonstrated improved 
glycemic control (A
1c
 reduction of -1.27% and -1.18% 
on empagliflozin 10 mg and 25 mg doses, respectively, 
compared with -0.81% on placebo) with lower insu-
lin doses (-9 to -11 IU/d) and weight loss (-1.95 kg and 
-2.04 kg on empagliflozin 10-mg and 25-mg doses, re-
spectively, compared with 0.44 kg on placebo.) There 
was no increased risk of hypoglycemia noted.
Adverse Effects and Precautions
Empagliflozin is generally well tolerated with low oc-
currence of AEs. Adverse effects reported in the pooled 
empagliflozin phase 3 studies were mild to moderate. Se-
rious AEs reported were higher in the placebo group as 
compared with those of the empagliflozin subjects but 
did not result in study discontinuation.33
Drug-drug studies of empagliflozin co-administered 
with other commonly prescribed medication in T2DM 
showed very limited, if any, interaction. Empagliflozin 
had no effect on the pharmacokinetics of warfarin or on 
its anticoagulant activity; therefore, these 2 drugs were 
deemed safe to be co-administered. No AEs were re-
ported when combining empagliflozin with the loop di-
uretic hydrochlorothiazide.33 Due to the mode of action 
of SGLT2 inhibitors, osmotic diuresis may result in a 
modest reduction in BP.34 
The FDA recently released a warning that SGLT2 
inhibitors may be associated with a higher risk of de-
veloping DKA.35 The FDA Adverse Event Report-
ing System identified 20 cases of DKA in patients 
treated with SGLT2 inhibitors from March 2013 to 
June 6, 2014. Diabetic ketoacidosis is typically accom-
panied by levels of ketone bodies > 3,000 μmol/L and 
develops almost exclusively in states of absolute insu-
lin deficiency. The highest level of ketone bodies ob-
served in patients receiving 25 mg of empagliflozin was 
1,449 μmol/L compared with a mean of 1,300 μmol/L 
in a nondiabetic overnight fast.36 Therefore, it is unlikely 
that the modest empagliflozin-induced ketosis would 
increase the risk of developing DKA in the absence 
of absolute insulin deficiency or extreme ketogenic 
diet.37 Physiologic explanation at the present time is 
not clear.
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The SGLT2 inhibitors are the latest of 14 classes of drugs 
approved to treat T2DM. This class offers many beneficial 
characteristics besides blood sugar lowering. The drugs 
lower systolic BP, induce weight loss through diuresis of 
glucose (calories), and carry low risks for hypoglycemia. 
The American Association of Clinical Endocrinologists 
recently published their 2015 diabetes management algo-
rithm.38 In this algorithm, they recognized metformin as 
first-line therapy along with diet and exercise intensifica-
tion for the treatment of T2DM. 
The glucagon-like peptide-1 (GLP-1) analogs and 
SGLT2 inhibitors are recognized as plausible second-line 
drugs. They go together well with metformin, providing 
powerful additional A1c-lowering effects while inducing 
weight loss without hypoglycemia. Because all GLP-1 an-
alogs are currently available only in injectable forms, the 
SGLT2 inhibitors offer the additional advantage of being 
available in pill forms.
CONCLUSIONS
All 3 of the current SGLT2 inhibitors are effective tools 
for treating T2DM. The 3 drugs share many similar traits, 
and efficacy is generally similar. Empagliflozin has the 
highest SGLT2 selectivity, > 2,500-fold selectivity for 
SGLT2 over SGLT1. However, canagliflozin has mild 
SGLT1 activity, which may offer additional benefits with 
regards to attenuating PPGE excursions by delaying in-
testinal glucose absorption (Table).
The SGLT2 inhibitor class had been shown to be effec-
tive when used as monotherapy as well as in combination 
with other oral antidiabetic medications. All 3 SGLT2 in-
hibitors have also been shown to be effective in com-
bination with insulin and have similar efficacy in these 
clinical settings (eTable).
All 3 SGLT2 inhibitors are generally well tolerated. 
There is less hypoglycemia compared with sulfonylureas. 
However, when the SGLT2 drugs are combined with drugs 
that can cause hypoglycemia, such as sulfonylureas and in-
sulin, patients must be monitored for hypoglycemia, and 
titrating down the sulfonylurea or insulin may be neces-
sary. Genital mycotic infections and urinary tract infections 
in men and woman are common AEs with SGLT2 drugs. 
Patients must be advised of these possible AEs, and treat-
ment should be prompt if these AEs occur. Because of the 
mild osmotic diuresis, patients should be reminded to keep 
well hydrated. SGLT2s have a very mild effect on increasing 
low-density lipoprotein cholesterol (LDL-C), so care should 
be taken to ensure that patients’ LDL-C stays at goal. 
The FDA recently released a warning that SGLT2 in-
hibitors may be associated with a higher risk of devel-
oping DKA. Although these reports are rare, clinicians 
should be vigilant. The FDA has suggested that patients 
should pay close attention for any signs of DKA and seek 
medical attention immediately if they experience diffi-
culty breathing, nausea, vomiting, abdominal pain, con-
fusion, and unusual fatigue or sleepiness.35
There are subtle differences in the eGFR thresholds for 
the use of the 3 drugs. It should be kept in mind that with 
all 3 drugs, the efficacy decreases as the eGFR decreases. 
It is recommended not to initiate canagliflozin if the pa-
tient’s eGFR is < 45 mL/min/1.73 m2. Dapagliflozin should 
not be initiated in patients with an eGFR < 60 mL/min/ 
1.73 m2. Empagliflozin should not be initiated in patients 
with an eGFR < 45 mL/min/1.73 m2. 
The SGLT2 inhibitors are useful tools to lower blood 
glucose levels in people with T2DM. They can be used as 
monotherapy or in combination. They also cause weight 
reduction. Thus, their unique mechanism of action is 
complementary to the other oral antidiabetic medications 
and insulin, so a wide variety of patients can benefit from 
this class.  
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